/HRTX

Heron Therapeutics Inc

HRTX

$0.32USD↓-2.11%-0.01 today

MARKET CAP

59.9M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$0 – $0

52W RANGE

$0

$2

AI Summary

Stalk

Sell NowMedium

HRTX remains in a Stage 4 decline with a clear sequence of lower highs and lower lows. Price trades below the 9, 21, and 50 EMAs, which continue to slope down and act as resistance. Although a Post-Capitulation pattern indicates selling exhaustion at the recent low, the absence of any repair above intermediate EMAs confirms medium-term bearish control. The tradable side is bearish, and execution should involve selling now into failed retests of the short-term EMAs. Key risks include a decisive reclaim of the 9/21 EMAs and a sustained break above the 50 SMA that could invalidate the downtrend.

↑APONVIE sales grew 74% YoY, driving surgical NK-1 segment momentum
↑Tax Benefit Preservation Plan extended to July 2029 enhances cash runway
↓Q2 net loss of $5.5M and $0.03 EPS missed consensus

Full analysis →

Buying

3

institutions

Selling

4

institutions

New Positions

0

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	10.55 M	4.50 M	+444.33 K	-44.3%	0.00%
MM Millennium Management LLC Q2 2026	SELL	4.07 M	1.74 M	+-3.56 M	-71.5%	0.00%
AC Aqr Capital Management LLC Q2 2026	BUY	1.55 M	663.19 K	+912.27 K	+29.2%	0.00%
RT Renaissance Technologies LLC Q2 2026	SELL	1.51 M	643.14 K	+-211.40 K	-53.2%	0.00%
JC Jpmorgan Chase & Co Q2 2026	BUY	75.67 K	32.95 K	+10.56 K	-32.1%	0.00%
CA Citadel Advisors LLC Q2 2026	SELL	47.10 K	20.10 K	+-767.77 K	-96.9%	0.00%
RC Rockefeller Capital Management L.P. Q2 2026	SELL	354.00	151.00	+-932.00	-85.3%	0.00%